0001193125-26-106453
SEC filingAspen Aerogels reported a net loss of $389.6 million for FY 2025, driven by a significant $291.2 million impairment of property, plant and equipment and a $378.2 million operating loss, despite generating $271.1 million in revenue. The company's gross profit was $46.0 million, yielding a gross margin of 17.0%. Operating cash flow was positive at $32.9 million, but net cash decreased by $62.7 million due to $37.4 million in capital expenditures and $58.1 million used in financing activities, primarily for debt repayments. The company ended the year with $406.7 million in total assets, $171.2 million in total liabilities, and $235.5 million in stockholders' equity. Key risks include customer concentration, with GM representing 59% of 2025 revenue, and reliance on a single manufacturing facility.
Aspen Aerogels reported a net loss of $389.6 million for the fiscal year ended December 31, 2025, a significant deterioration from net income of $13.4 million in 2024. This loss was primarily driven by a $291.2 million impairment of property, plant and equipment and a $378.2 million operating loss. Revenue for the year was $271.1 million, with cost of revenue at $225.1 million, resulting in a gross profit of $46.0 million and a gross margin of 17.0%. The company's operating expenses totaled $424.2 million, including $13.4 million in research and development, $28.2 million in sales and marketing, $55.8 million in general and administrative, $17.5 million in restructuring costs, and the aforementioned impairment charge.
Revenue of $271.1 million was generated primarily from sales to a limited number of direct customers, with the top ten customers representing 84% of total revenue. General Motors (GM) accounted for 59% of total revenue in 2025, down from 64% in 2024, while Distribution accounted for 9%. International sales represented 37% of total revenue ($99.0 million), with shipments to Mexico, China, United Arab Emirates, Thailand, Malaysia, Sweden, France, Singapore, South Korea, Canada, Japan, and Australia. The company noted that GM reduced its demand for aerogel products in 2025, which had a significant adverse impact on business operations.
The company's gross margin was 17.0% for FY 2025, with gross profit of $46.0 million on $271.1 million in revenue. Operating margin was negative 139.5% due to the $378.2 million operating loss. The significant impairment charge of $291.2 million on property, plant and equipment was the primary driver of the operating loss. Other contributing factors included $17.5 million in restructuring and demobilization costs and an $18.2 million loss on disposal of property, plant and equipment. The company's cost structure remains challenged by high fixed costs and underutilized manufacturing capacity.
Operating cash flow was positive at $32.9 million for FY 2025, compared to $45.5 million in 2024. However, net cash decreased by $62.7 million due to $37.4 million used in investing activities (primarily capital expenditures) and $58.1 million used in financing activities. Financing activities included $150.0 million repayment of convertible note, $26.0 million repayment of term loan, and $5.8 million in issuance costs, partially offset by $125.0 million proceeds from term loan and $43.0 million proceeds from revolving line of credit. The balance sheet shows total assets of $406.7 million, including $242.1 million in current assets ($156.9 million cash and equivalents) and $98.4 million in net property, plant and equipment. Total liabilities were $171.2 million, with $62.0 million in current liabilities. Stockholders' equity was $235.5 million, with accumulated deficit of $1.05 billion.
The company faces significant risks including customer concentration (GM represented 59% of 2025 revenue), reliance on a single manufacturing facility in East Providence, RI, and external manufacturing facilities in China. Management noted that GM reduced demand in 2025 and further reductions could adversely impact business. The company requires additional capital to pursue its growth strategy but may not be able to obtain financing on acceptable terms. While operating cash flow was positive in 2025 and 2024, the ability to continue generating positive cash flow is uncertain. The company is subject to covenants under its Amended MidCap Loan Facility and must maintain minimum liquidity thresholds. A fire at the East Providence facility in February 2026 damaged an emissions control unit, which may impact manufacturing capacity until replacement in the second half of 2026.